A multidisciplinary approach to the diagnosis of antisynthetase syndrome

Matthew Wells ◊ 1, Sughra Alawi2, Kyaing Yi Mon Thin2, Harsha Gunawardena1,2†, Adrian R. Brown3, Anthony Edey2‡, John D. Pauling ◊ 1,2†, Shaney L. Barratt ◊ 2‡ and Huzaifa I. Adamali ◊ 1

1 Department of Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom. 2 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, United Kingdom. 3 Immunology Laboratory, North Bristol NHS Trust, Bristol, United Kingdom

Antisynthetase syndrome is a subtype of idiopathic inflammatory myopathy, strongly associated with the presence of interstitial lung disease. Diagnosis is made by identifying myositis-specific antibodies directed against aminoacyl tRNA synthetase, and relevant clinical and radiologic features. Given the multisystem nature of the disease, diagnosis requires the careful synthesis of subtle clinical and radiological features with the interpretation of specialized autoimmune serological testing. This is provided in a multidisciplinary environment with input from rheumatologists, respiratory physicians, and radiologists. Differentiation from other idiopathic interstitial lung diseases is key; treatment and prognosis differ between patients with antisynthetase syndrome and idiopathic interstitial lung disease. In this review article, we look at the role of the multidisciplinary team and its individual members in the initial diagnosis of the antisynthetase syndrome, including the role of physicians, radiologists, and the wider team.

KEYWORDS
antisynthetase syndrome, myositis, interstitial lung disease, arthritis, connective tissue disease, multidisciplinary team

Introduction

Antisynthetase syndrome (ASyS) is a subtype of idiopathic inflammatory myopathy (IIM), strongly associated with the presence of interstitial lung disease (ILD) and aminoacyl tRNA synthetase antibodies (antisynthetase antibodies). Although the presentation is heterogeneous, the classical clinical features include but are not limited to the triad of ILD, myositis, and arthritis (1, 2). The antisynthetase antibody target antigen, aminoacyl tRNA synthetase, resides within the cytoplasm of cells and plays a role in the translation of mRNA into protein, yet the antibody's role in the aetiopathogenesis is undetermined (3).
Given prominent pulmonary and musculocutaneous clinical features, ASyS represents a true interdisciplinary multisystem disease presenting to both respiratory and rheumatology services. The diagnosis requires the careful evaluation of clinical features, radiology, and expertise in the interpretation of serological tests. This is best provided in a multidisciplinary setting wherein accurate diagnosis and treatment decisions are shared among clinical and diagnostic teams. This review will evaluate the multidisciplinary approach to the diagnosis of ASyS, referring to the clinical and serological features observed in the spectrum of disease.

Classification and epidemiology

Classification criteria are developed to identify a homogeneous cohort of patients from an existing population group of interest for recruitment into research studies. Two sets of classification criteria for ASyS were published in 2010 and 2011 based on expert consensus, both acknowledging the presence of aminoacyl tRNA synthetase antibodies as necessary for classification alongside the presence of specific clinical features (4, 5). To date, eight antibodies have been described in the literature: anti-Jo1, the most frequently observed in up to 88% of ASyS patients (6), anti-PL7, anti-PL12, anti-OJ, anti-EJ, anti-KS, anti-Zo, and anti-SC (3) (Table 1). The 2017 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups do not acknowledge ASyS as a distinct entity, and anti-Jo1 antibody was the only myositis-specific antibody included in the final classification criteria due to the underrepresentation of other antibodies (7). It has been shown that the inclusion of the other antisynthetase antibodies in the EULAR/ACR classification criteria improves sensitivity for ASyS (8), but there are concerns that this may compromise specificity (9, 10).

Presently, no data driven or validated classification criteria exist for ASyS and definitions vary widely across the literature and are poorly evidenced (11). Project CLASS is an ongoing large multicentre international effort funded by EULAR and ACR aiming to develop a validated criteria set for ASyS. This large-scale study should lead to more representative ASyS patient recruitment in future research studies and may further our understanding of the influence of the antisynthetase antibody serology on disease phenotype.

The epidemiology of ASyS is unclear. A study in inner-city Manchester revealed a mean incidence of IIM of 17.6/1,000,000 person-years, of which 28% were identified as ASyS by expert consensus (12). Females are affected more frequently than males, and the mean age at onset ranges from 43 to 60 years (13). Data suggest that black patients may have more frequently occurring and severe ILD but ASyS epidemiology does not otherwise appear to be influenced by ethnicity (14, 15). Older studies with varying disease definitions, failure to include the more recently discovered antisynthetase antibodies, and lack of the aforementioned data-driven classification criteria have impacted reported epidemiology.

Clinical features

The classical triad of ILD, myositis, and arthritis was reported at first presentation (defined as the development of all three features within 3 months of first symptom onset) in only 5% of the large international American and European Network of Antisynthetase Syndrome (AENEAS) cohort, including anti-Jo1, anti-PL7, anti-PL12, anti-EJ, and anti-OJ antibody-positive patients and 15% of a Chinese cohort of antisynthetase antibody-positive ILD patients (16, 17). In the AENEAS study, the onset was predominantly a single triad feature in all included antibody subgroups, suggesting the condition can frequently present as isolated ILD, myopathy, or arthritis. It concluded that presentation and disease course between antibody groups is broadly similar. However, this observation is inconsistent across the literature; a 2014 meta-analysis including 3,487 patients suggested a higher prevalence of ILD in non-anti-Jo1 and myositis in anti-Jo1 patients (18).

A significant proportion of patients in the AENEAS cohort developed additional clinical features during the follow-up (16).
Beyond the classical triad, there are several other commonly occurring features as outlined below, alongside other less well-reported examples of organ involvement that can significantly impact morbidity and mortality.

**Pulmonary disease**

ILD has a prevalence of 67 to 100% in ASyS, with cough and dyspnoea the most common symptoms (19, 20). Some reports suggest a greater prevalence of ILD in anti-PL7 and anti-PL12 positive patients when compared to the more frequently encountered anti-Jo1. The John Hopkins myositis center cohort observed isolated lung involvement at disease onset in anti-PL7 and anti-PL12 patients at 56 and 65%, respectively, compared to only 26% among patients with anti-Jo1 disease (14). After 3.4 years of follow-up, 19% of anti-PL7 and 30% of anti-PL12 patients had failed to develop myositis. Hervier's cohort described more severe ILD in anti-PL7 and anti-PL12 diseases with lower forced vital capacity (FVC) and concomitant poorer survival when compared to anti-Jo1 cases (21).

This contrasts with the findings of the previously mentioned AENEAS cohort (16). Further analysis of the anti-Jo1 positive patients in AENEAS showed that 21% presented with isolated pulmonary symptoms. At follow-up (median 72 months), ILD was observed in 82% of anti-Jo1 patients, 20.8% of whom were asymptomatic. Other cohorts have also failed to show differences in ILD severity according to serology (22).

The timing of presentation of ILD in the disease course can be variable. Pulmonary symptoms may present early, as seen in “lung dominant disease,” develop simultaneously alongside other symptoms, or may appear later in the course of the disease (16, 23). We have seen locally that patients referred to respiratory services with ILD are more likely to have amyopathic disease concurring with the findings of Hervier and colleagues (21, 24); interestingly, our respiratory cohort did not have significantly different lung function abnormalities compared to those presenting to rheumatology.

Other forms of ILD must be considered. Idiopathic pulmonary fibrosis (IPF) patient demographics frequently differ from those of ASyS and other connective tissue disease-associated ILD (CTD-ILD), being predominantly male and of older age at onset (25). However, a significant proportion of ASyS and IPF patients may overlap demographically, and this can contribute to missed or delayed diagnosis (24).

Plural involvement has been reported in ASyS; a recent study including 93 patients observed that 42.2% had pleural effusions (26). Anti-Jo1 patients appeared less likely to suffer pleural effusions than non-anti-Jo1 patients. Serositis is not widely reported in the literature but given its prevalence in this cohort, this is an area that needs further evaluation.

**Assessment of lung disease**

**Physiology**

We would recommend spirometry, lung volumes, diffusion capacity, and a 6-min walk test in all patients with suspected ILD. These measurements of lung physiology help assess the severity and pattern of respiratory impairment.

Physiological impairment in ILD-related ASyS is a restrictive lung pattern with a decreased diffusion capacity for carbon monoxide (DLco). Serial PFTs are helpful for disease monitoring, prognostication, and response to treatment (27, 28); a relative decline of FVC of 10% or greater, or 5 to 10% with clinical deterioration has been considered to suggest ILD progression (29).

A disproportionate reduction in the FVC compared to the radiological lung interstitial abnormalities may indicate diaphragmatic or respiratory muscle weakness; hence, measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) may be helpful. MIP represents the strength of the inspiratory muscles including the diaphragm, and MEP reflects the strength of the expiratory muscles. Normal MIP usually excludes significant diaphragmatic involvement (30). Performance status can be assessed and quantified using the 6-min walk test, with saturation probe measurement to identify dips in oxygen saturation. Performance can be influenced by non-pulmonary aspects of ASyS such as myopathy and Raynaud’s and should be interpreted accordingly.

**Imaging**

High-resolution computed tomography (HRCT) plays a critical confirmatory role in the diagnosis of ILD. Ground glass opacities (hyper-attenuated areas with preserved bronchial and vascular markings), linear opacities, reticulations, and traction bronchiectasis (bronchial distortion caused by mechanical traction by the fibrosis) are frequently seen in ASyS. Areas of consolidation (hyper-attenuated areas with loss of normal bronchial and vascular markings) also may be seen (3, 31, 32).

Common radiological patterns described in ASyS are non-specific interstitial pneumonitis (NSIP), organizing pneumonitis (OP), and NSIP/OP overlap (Figure 1). Less commonly, usual interstitial pneumonitis (UIP) and acute interstitial pneumonitis (AIP) have been reported (3, 24, 32–34). There is no clear association between the different HRCT patterns and the different antisynthetase antibodies, and all patterns are seen across all antibody subtypes.

However, multiple cohort studies have shown a broad spectrum of ILD manifestations on HRCT scans. In a large Chinese cohort, the spectrum varied from an OP pattern predominantly seen in anti-Jo1 positive ASyS with an NSIP...
HRCT images of ILD patterns seen in ASyS. All patients are positive for anti-Jo1 antibody and have an MDT diagnosis of ASyS. (A) Axial view of fibrotic NSIP demonstrating patchy ground glass opacification with reticulation and traction airway dilatation. (B) Sagittal view of fibrotic NSIP demonstrating the lower zone predominance in the same patient. (C) Axial view of organizing pneumonia with patchy, peripheral basal predominant consolidation; (D) Axial view showing UIP pattern with subpleural basal predominant reticulation and extensive honeycombing evident.

pattern evident in anti-PL12 and anti-PL7. In anti-EJ patients, an OP pattern was most predominantly seen (35). Other smaller cohorts have shown overlap NSIP/OP patterns to be more prevalent in anti-Jo1 and anti-PL12 (36).

**Other tests**

ILD guidelines recommend routine serological testing in all patients with newly identified ILD, including for anti-nuclear antibodies (ANA) by immunofluorescence, with onward referral to rheumatology, if there are extra-pulmonary connective tissue disease (CTD) features or positive serologies (25). Often no invasive investigations are required and the presence of ILD with circulating antisynthetase antibodies is sufficient for multidisciplinary diagnosis.

Bronchoalveolar lavage (BAL) is unlikely to change a clinical and serological diagnosis of CTD-ILD (37). While BAL fluid cytology has been described in various subtypes of ILD, findings are non-specific, and therefore the role of BAL in ASyS assessment is limited. It may be performed in cases of non-UIP type ILD presenting without CTD features or if infection or pulmonary hemorrhage are considered in the differential diagnosis (38).

Lung biopsies including open, video-assisted thoracoscopic surgery and cryobiopsy, are not routinely performed. The main histological patterns identified are NSIP and OP. UIP and diffuse alveolar damage (DAD) are less frequently seen;
one study has suggested that UIP is more common in anti-PL12 disease (39). Histopathological findings usually correlate with the HRCT pattern (40). Multidisciplinary consensus with improved imaging technology has significantly reduced the need for invasive procedures (41). When there is a failure to reach a consensus diagnosis, lung biopsy may remain an option to support the overall multidisciplinary impression.

**Myopathy**

Myopathic muscular weakness was observed in 91% of ASyS patients in the cross-sectional EuroMyositis registry (20). The AENEAS cohort describes myositis present in 56.1% of anti-Jo1 patients at disease onset, of which 15.2% were subclinical, detected by elevation of muscle enzymes or EMG alone without clinically apparent weakness. This rose to 82.1% at 72 months follow-up, with the only significant difference between antibody subgroups being more infrequent myositis in anti-PL12, with 30% at onset rising to 43% at 37.5 months follow-up (16). More frequent myositis in anti-Jo1 has also been observed in other cohorts (21). Amyopathic patients are more likely to present to respiratory services, where co-existent myalgia or elevated creatine kinase (CK) was relatively uncommon at 30% in Barratt et al.’s cohort (24).

The spectrum of myopathy may range from subclinical disease to significant proximal weakness, causing difficulties rising from a seated position, climbing staircases, or reaching overhead cupboards (42). Persistent myalgia and muscular tenderness are reported in 30.4 to 88.9% of cases (2, 43, 44). Weakness may be elicited on examination and should be quantified using manual muscle testing of eight muscle groups (MMT8 score); this is a standardized power assessment tool for myositis patients used by rheumatologists with excellent reproducibility (45).

**Assessment of myopathy**

Investigations should aim to confirm the clinical impression of myopathy, with simultaneous scrupulous assessment for the ancillary features of ASyS described below, which can represent 20 to 25% of all IIM cases (46). This initially consists of the measurement of serum levels of the muscle enzymes creatine kinase (CK) and aldolase. Cardiac Troponin T (cTnT), lactate dehydrogenase (LDH), and alanine transferase (ALT) can also be elevated during skeletal muscle inflammation. Levels of CK elevation vary with a mean level of 4,288 U/L, but as high as 22,820 U/L in one Japanese cohort of ASyS patients presenting with limb muscle weakness (47), yet these muscle enzymes are neither sensitive nor specific and it should be cautioned that this Japanese study recruited patients with clinically apparent myopathy, thus excluding clinically amyopathic ASyS patients. Muscle enzymes may be normal, and while they can be useful markers of disease activity, they do not necessarily correlate with myositis activity, especially in more chronic diseases. British Society of Rheumatology guidelines recommend testing for myositis antibodies in patients with suspected inflammatory myopathy (48), and in the correct clinical context, these may be diagnostic.

If there is clinical uncertainty, multidisciplinary support from neurophysiologists and musculoskeletal radiologists can facilitate confirmation of myopathy in IIM. Electromyography shows early recruitment of motor unit potentials with spontaneous activity, a highly suggestive pattern for IIM (49). Sensitivity is reported to be as high as 93.8% for ASyS, but this deteriorates with concomitant glucocorticoid exposure, and findings lack specificity for the IIM subtype (50). Magnetic resonance imaging (MRI) with T2 weighted imaging (T2WI) and short tau inversion recovery (STIR) sequencing detecting muscular and fascial edema and fatty replacement can be seen in as many as 65% of ASyS patients (51) (Figure 2). More chronic myositis changes are seen with T1 weighted imaging (T1WI) as atrophy with fat replacement (52).

Muscle biopsy is rarely required to confirm a diagnosis of ASyS. It can, however, be indispensable in ruling out alternative causes of myositis, such as muscular dystrophies, metabolic, infectious, toxin/drug-mediated disease, and inform the decision to commence immunosuppressive treatment regimes (53). MRI can be used to target and increase muscle biopsy sensitivity (52).

When performed, muscle biopsy with findings of mononuclear cell infiltrates and muscle fiber necrosis are supportive of a clinical impression of IIM and may help determine dermatomyositis (DM)/inclusion body myositis (IBM) and Immune-mediated necrotizing myopathy (IMNM) (53, 54). Necrotizing myopathy is the most common finding in antisynthetase antibody-positive patients. When DM and IBM samples were excluded, myofiber HLA DR expression is highly specific in muscle biopsy specimens from antisynthetase antibody-positive patients, although the utility of this finding is yet to be fully understood (55). With the growing availability of commercial serological assays for identifying antisynthetase antibodies, there is less need for muscle biopsy for the diagnosis of ASyS. Muscle histology still has an important role in cases where the clinical picture of IIM is incomplete, for example, if there are no obvious CTD features or where a circulating myositis-specific antibody cannot be identified (48).

**Arthritis**

Arthritis is widely documented as a symmetrical, non-erosive polyarthritis of the small joints of the hands and feet in ASyS (56), mimicking seronegative inflammatory, rheumatoid, and CTD-associated arthritides. It is a non-specific symptom
Raynaud’s phenomenon

Raynaud’s phenomenon is typically a cold-provoked peripheral ischemia manifested clinically by a digital color change from white (Figure 3A) to blue and then red (classical “triphasic” Raynaud’s), and can be primary or secondary to another disease process. Prevalence is self-reported as 4.6% among adults in Great Britain, most of whom are primary (63). Primary Raynaud’s occurs without a disease association, typically with onset in young (under 30 years old) females with symmetrical episodic attacks precipitated by the cold without ulceration or tissue compromise, and often with negative or non-specific ANA tests (64).

Age over 30 years at onset may raise suspicion for secondary Raynaud’s phenomenon, alongside more frequent attacks, more significant pain during onset, and asymmetry than with primary Raynaud’s. It is seen associated with CTD, such as systemic lupus erythematosus (SLE), mixed-connective tissue disease (MCTD), and systemic sclerosis (SSc), as well as ASyS, where it was reported in 51% of the 512 cases in the EuroMyositis registry (20). While severe secondary Raynaud’s may progress to digital ischemia and ulceration in SLE and SSc, this is seldom seen in primary Raynaud’s and ASyS (65).

At a microvascular level, nail-fold videocapillaroscopy (NVC) is abnormal in ASyS compared to a control population of primary Raynaud’s patients (66). In this study, ASyS patients demonstrated reduced capillary density, more severe microhemorrhages, and more giant capillaries than the control population. These findings are not specific to ASyS and may be seen in other CTD, including SSc. Further research needs to be performed to clarify any potential role for NVC, it may play a role in the diagnosis and monitoring of ASyS in future (67).

Mechanics hands and DM-like rash

Mechanics hands refer to roughening and cracking of the skin of the lateral aspects of the fingers, typically the radial border of the index and ulnar border of the thumb (Figure 3B). This was reported in 38% of ASyS cases included in the...
Figure 3

(A) Raynaud’s phenomenon, initial vasoconstriction causing pallor, which usually progresses to cyanosis then reactive hyperemia in triphasic Raynaud’s; (B) Mechanic’s hands, hyperkeratotic, fissured skin predominantly visible over the radial border of the index finger.

Raynaud’s phenomenon, initial vasoconstriction causing pallor, which usually progresses to cyanosis then reactive hyperemia in triphasic Raynaud’s; (B) Mechanic’s hands, hyperkeratotic, fissured skin predominantly visible over the radial border of the index finger.

EuroMyositis registry (20). Mechanics hands do not appear to have any prognostic value and are also seen in DM and OM, albeit less frequently (68). On biopsy, an interface psoriasiform dermatitis is seen (69).

A DM-like rash is observed in 32 to 44% of patients with antisynthetase antibodies (18). This includes psoriasiform-type lesions extending across the dorsum of the hand morphologically similar to those observed in mechanics hands, Gottron papules, and heliotropic rash.

While these rashes may be part of the heterogeneous ASyS disease spectrum, they may also be suggestive of DM or OM and MSA/MAA may help to determine the serological diagnosis. Such differentiation between ASyS and DM is clinically and prognostically important given differing profiles of malignancy risk and evidence suggesting that ILD associated with ASyS may carry a better prognosis than when associated with other IIM (70).

Fever

Fever when present should prompt investigation for infection, although the reported prevalence in ASyS ranges from 21 to 66% (23, 71). A Chinese cohort study identified more pyrexial episodes with acute phase response in anti-PL7 (50%) and anti-Jo1 (30%) positive cases, with a more inflammatory phenotype predictive of rapidly progressive ILD (RP-ILD) (72).

The large 2014 meta-analysis demonstrated more fever in non-anti-Jo1 patients as opposed to anti-Jo1 positive patients (18). Neither the AENEAS nor EuroMyositis cohorts present data on fever prevalence.

Other CTD manifestations

Several other manifestations of the disease are described in the literature. Cardiac involvement, including pulmonary hypertension (PH), was seen in 7.9% of a multicenter French retrospective study, with subsequent significant impact on survival, although felt to be secondary to co-existent ILD (73). The authors conclude that clinicians should consider routine screening for PH in ASyS patients. This should be suspected when the degree of dyspnoea is disproportionate to the burden of disease on HRCT or if there is a strong SSc phenotype. Antisynthetase antibodies are sometimes present in patients with SSc, highlighting the significant clinical overlap that may exist between IIM and SSc spectrum disorders (74). DLco may also be disproportionately low compared to other lung function testing parameters. PH is presumed secondary to ILD, however, subgroups of ASyS patients with PH appear to have severe PH with relatively mild ILD, raising suspicion for a pulmonary vasculopathy as seen in SSc patients with group 1 PAH (75).

Another study reported a prevalence of myocarditis of 3.4% without any link to antibody specificity but all cases presented...
with active myositis (76). As mentioned previously, cTnT may be elevated in active myositis, whereas cardiac Troponin I (cTnI) is more specific for myocardial disease and although not universally available, it may be a helpful non-invasive screening test for primary cardiac involvement (77).

Analysis of a small cohort looking at the manifestations of disease not included in the classification criteria suggested that dysphagia (27%), DM rash (24.3%), and sicca symptoms (24.3%) commonly occur (78).

**Autoimmune serology**

The presence of ANA is seen in association with various "ANA-associated rheumatic diseases" including the IIM alongside SLE, SSc, Sjogren’s syndrome (SS), and M-CTD. They are also seen in other non-rheumatic diseases (autoimmune liver disease) and are present in up to 13.3% of otherwise healthy individuals at a 1:80 dilution (79). ANA is a collective term for a heterogeneous group of antibodies directed against cell components, traditionally within the nucleus. However, many target antigens are located outside the nucleus leading some commentators to suggest that they may be better considered "anti-cell antibodies" (80).

Over recent decades, the discovery of multiple MSA and MAA within the ANA spectrum has revolutionized the understanding of IIM and allowed researchers to identify distinct serologically defined phenotypes. Detection of these specific autoantibodies now plays a vital role in the diagnosis of ASyS. Immunoprecipitation (IP) is the gold standard detection method for autoantibodies, given its superior sensitivity and specificity. However, it is only available in a few specialized centers, limiting its use to research rather than clinical settings (81, 82).

Screening for the presence of ANA by immunofluorescence (IF) on HEp2 cell lines is recommended by the ACR as the gold standard ANA screening technique (83). HEp2 cells display a range of antigens not included in other ANA detection techniques and also present the advantage of providing the cellular location of any target antigens as well as titer levels (Figure 4). If ANA by IF is positive, more specific tests are performed on the patient serum to identify antigen specificity. Historically, this comprises assays for the six most common antibodies, which only include one antisynthetase antibody (anti-Jo1).

Importantly, screening by HEp2 ANA and other techniques may be negative but the presence of a cytoplasmic staining pattern under fluorescent microscopy suggests the presence of antibodies. This was well-demonstrated in a 2017 study showing that 82% of ANA-negative ASyS patients had positive cytoplasmic staining on IF and this pattern had high sensitivity and specificity for the presence of antisynthetase antibodies (84). In the setting of a high pre-test probability, extended assaying for disease-specific antibodies should be performed on these samples, such as the myositis blot. The results of these tests should then be interpreted in conjunction with the IF staining pattern and clinical correlation. Antisynthetase antibodies should correlate with a cytoplasmic staining pattern on IF and this improves the positive predictive value (85).

IF is labor intensive and dependent upon the availability of trained technicians who are able to report staining patterns. Despite efforts to standardize testing, reporting of patterns and differing cell lines in use can all limit IF (86). Subsequently, other techniques such as enzyme-linked immunosorbent assays (ELISA), chemiluminescence, and bead technology are also in use, with the advantages of reduced costs, higher throughput, and less dependence on trained laboratory staff. Given the significantly reduced antigen profile as compared to IF on HEp2 cells, sensitivity is lacking and no information on antibody binding patterns is provided. These differing antigen profiles and limitations must be considered when relying on non-IF detection patterns and MSA should be tested for where there are cutaneous, pulmonary, or vascular (Raynaud’s) features suggestive of IIM, even if ANA testing is negative by these techniques.

Further extended testing for MSA and MAA, which include the antisynthetase antibodies, is performed by line or dot blot technology (Figure 5). Recent work suggests that these tests have poor sensitivity for the less common anti-OJ, anti-EJ, and anti-PL7 antibodies (87). Commercial immunoblots are also liable to false positives; the previous study reported that 16.1% of healthy controls tested positive for an MSA. Results must always be interpreted in the context of the immunofluorescence pattern, clinical-radiological presentation, and strength of positivity (88).

Notably, the anti-Ro52 antibody is found in a significant proportion of ASyS patients and appears to correlate with the presence and severity of IBD (89). It is detected in concert with the aminocyl tRNA synthetase antibodies on an extended myositis blot and may be informative in terms of prognosis and guiding initial treatment strategies as well as a surrogate marker of ASyS (90).

**Multidisciplinary team assessment**

The initial secondary care assessment of ASyS patients usually takes place in respiratory or rheumatology clinics given the wide prevalence of arthritis, myositis, and pulmonary disease. However, the condition may also initially present to neurology or dermatology, given the possibility of prominent weakness or cutaneous disease at the time of onset.

Increasingly, combined rheumatology and respiratory clinics are becoming more common place (91). These allow for expert assessment for clinical features suggestive of autoimmune rheumatic disease and interpretation of complex autoimmune serological tests by a rheumatologist.
Indirect immunofluorescence demonstrating "anti-nuclear" antibody bound to (A) Cytoplasm as seen in ASyS; (B) Homogeneous nuclear binding as seen in SLE, autoimmune hepatitis, and juvenile idiopathic arthritis; (C) Centromere binding as seen in limited cutaneous SSC with anti-centromere antibody positivity. Images courtesy of ANApatterns.org—with permission.

Algorithm depicting ANA assaying in ASyS. Extended testing is advised in the context of a cytoplasmic pattern on IF. If alternative ANA screening methods are used and suspicion of ASyS or IIM remains high, it may be appropriate to perform extended testing, especially when certain potentially relevant MSA or MAA are not included in the screening antigen profile and there are cutaneous, pulmonary, or vascular features of IIM. Respiratory specialist presence facilitates diagnosis with the aid of advanced physiological assessment and radiological investigations. The exclusion of idiopathic, drug-related, and environmental causes for lung disease is of paramount importance (92).

Clinical features should be assessed and confirmatory investigations arranged as above with findings carefully documented. Combined clinics not only influence clinical and therapeutic outcomes but are also a time and cost-effective way of providing quality care to ASyS patients (91).
If after this assessment, ASyS or alternate CTD-ILD is suspected, cases should be referred onwards for discussion in regular multidisciplinary team meetings. This gold standard multidisciplinary team (MDT) meeting provides an evidence-based diagnostic and management decision platform (25, 93–95). The diagnostic quorum includes members who have a special interest in CTD-ILD. The inclusion of rheumatologists reduces the need for invasive procedures to secure diagnosis (96). Thoracic radiologists play a key role in determining ILD patterns and expert interpretation of HRCT scanning. Radiology is essential; data show that clinicians change their diagnosis based on HRCT findings in up to 51% of ILD cases (97). Respiratory physicians with a specialist interest in ILD can clinically correlate radiological findings and pulmonary physiology.

Our experience also supports the value of a formal CTD-ILD MDT comprising ILD nurse specialists, dedicated ILD pharmacists, research nurses, a registry coordinator, and auxiliary specialties who facilitate delivery of oxygen therapy, pulmonary rehabilitation, high-cost drugs, clinical trials, management of registries, symptom control, and palliation (Figure 6).

The centralization of these specialist services into a regional MDT facilitates center experience, networking, case
In the correct clinical context, invasive procedures are rarely required (41). For incomplete cases, such as those without a detectable circulating antibody or atypical radiology, the MDT is well-placed to arrange surgical lung or muscle biopsies to better inform any decision to treat with immunosuppressive therapy. As discussed earlier, histology may be supportive but is non-specific for ASyS. It can, however, be crucial in ruling out alternative causes. In the presence of a compatible clinical phenotype, cytoplasmic staining pattern on IF, and detectable Ro52, it may be possible to make an MDT diagnosis of ASyS without invasive procedures or a specific detectable antisynthetase antibody. Consequently, it is important to recognize that real-world MDT diagnoses do not always correlate with current classification criteria and this limitation should be considered when reviewing patients.

ASyS patients should be followed-up regularly and any change in clinical condition should prompt rediscussion within the MDT, wherein decisions regarding disease progression, treatment response, and new organ involvement can be raised and discussed among all members. Importantly, clinical trial nurse specialists should advise on the potential eligibility of patients for existing available trials.

**Conclusion**

ASyS patients represent a clinically and serologically distinct subgroup of both IIM and ILD patients. Within the broad spectrum of ASyS, it is unclear to what degree serology influences presentation and prognosis. It may be that anti-Jo1 patients represent a more musculoskeletal phenotype of disease with less severe ILD, whereas non-anti-Jo1 patients have more aggressive ILD, possibly associated with decreased survival (18). This heterogeneity across cohorts is likely confounded by differing study methodologies, case definitions, antibody detection techniques and thresholds, and patient assessments with variable follow-up (1, 18, 43).

Diagnosis is a gestalt process—considering clinical features, imaging characteristics, and immunology, usually with aminoacyl tRNA synthetase antibody detection and appropriate cytoplasmic staining on IF. This should be confirmed within a diagnostic and management CTD-ILD MDT setting. If the clinical picture is incomplete or serological testing is inconclusive, the threshold for targeted muscle or lung biopsy should be lowered to ensure that important differential diagnoses are not missed and inappropriate immunosuppression is not offered.

The MDT has evolved to become a platform not only for the initial assessment but also with upcoming new treatments and the introduction of antifibrotic agents, an opportunity to hone down the diagnosis and provide holistic and complete care for ASyS patients.

**Author contributions**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**Funding**

Funding for the publication of this article has been kindly provided by the Bristol Interstitial Lung Disease Research Fund.

**Acknowledgments**

The authors thank Sarah Rudd, librarian, North Bristol NHS Trust and also Dr Chan and Dr Andrade of ANApatterns.org.

**Conflict of interest**

HG has received speaker and advisory fees from Boehringer-Ingelheim. JDP has received personal support from and undertaken consultancy work for
Janssen, Astra Zeneca, Permeatus Inc, Boehringer-Ingelheim and Sojournix Pharma. SLB has undertaken consultancy work and received speaker honoraria from Boehringer-Ingelheim.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Hervier B, Renveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. (2013) 15:349. doi: 10.1007/s11926-013-0349-8

2. Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. (2021) 51:845–52. doi: 10.1111/imj.15338

3. Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Palm Med. (2016) 23:218-26. doi: 10.1097/CPM.0000000000000171

4. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. (2010) 138:1464-74. doi: 10.1378/chest.10-0180

5. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Brasil Pneumol. (2011) 37:100–9. doi: 10.1590/S1677-78802011000100015

6. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J. (2011) 41:674–9. doi: 10.1111/j.1445-5994.2010.02164.x

7. Bottoli M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, et al. EULAR/AACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. (2017) 3:e000507. doi: 10.1136/rmdopen-2017-000507

8. Greco M, García de. Yebenes MJ, Alarcón I, Brandý-García AM, Rúa-Figueroa I, Loza E, et al. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. Ann Rheum Dis. (2019) 78:1291–2. doi: 10.1136/annrheumdis-2019-215031

9. Knitza J, Cavagna I, Schett G, Dusler JHW. Comment on: ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al. by Knitza et al. Ann Rheum Dis. (2020) 79:e86. doi: 10.1136/annrheumdis-2019-215515

10. Tjarnlund A, Lundberg JE. Response to ‘Comment on: “Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria” by Greco et al. by Knitza et al.’ Ann Rheum Dis. (2020) 79:845. doi: 10.1136/annrheumdis-2019-215484

11. Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Cortez TJ, Doyle TJ, et al. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol. (2022) 40:39-19. doi: 10.5556/ClinExpRheumatol/rtx069

12. Parker MJS, Oldroyd A, Roberts ME, Ollier WE, New RP, Cooper RG, et al. Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatol Adv Pract. (2018) 2:ryk035. doi: 10.1093/rheumatology/kyr035

13. Legout L, Fauchais AL, Hachulla E, Queyrel V, Michon-Pasturel U, Lambert M, et al. The antisynthetase syndrome: a subgroup of inflammatory myopathies not to be unrecognized. La Rev Méd Interne. (2002) 23:273–82. doi: 10.1016/S0248-8663(01)00552-5

14. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Alhaya B, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology. (2017) 56:999–1007. doi: 10.1093/rheumatology/kex021

15. Chua F, Highton AM, Colebatch AN, O'Reilly K, Gruban C, Vlahos I, et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology. (2012) 51:1870–6. doi: 10.1093/rheumatology/kes167

16. Cavagna I, Trallerio-Araguis E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. (2019) 8:2013. doi: 10.3390/jcm8112013

17. Jiang M, Dong X, Zheng Y. Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. Medicine. (2021) 100:e25816. doi: 10.1097/MD.0000000000025816

18. Lega J-C, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. (2014) 13:883–91. doi: 10.1016/j.autrev.2014.03.004

19. Cojocaru M, Cojocaru DM, Chicos B. New insights into antisynthetase syndrome. Maedica. (2016) 11:130–5.

20. Lilker JB, Vencovský J, Wang G, Wedderburn LR, Diderichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. (2018) 77:30–9. doi: 10.1136/annrheumdis-2017-211868

21. Hervier B, Devillers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. (2012) 12:210–7. doi: 10.1016/j.autrev.2012.06.006

22. González-Pérez M, Mejía-Hurtado JG, Pérez-Román DJ, Ruenda-Roldin L, Mejía M, Fafán Valencia R, et al. Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies. J Rheumatol. (2020) 47:415–25. doi: 10.3899/jrheum.181141

23. Masak A, Marzee M, Kulczycka J, Zdrojewski Z. The clinical phenotype associated with antisynthetase autoantibodies. Reumatologia. (2020) 58:4–8. doi: 10.5114/reum.2020.93505

24. Barratt SL, Adamali HH, Cotton C, Mulhearn B, Ifitkhar H, Pauling JD, et al. Clinicoserological features of antisynthetase syndrome-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services. RMJ Open Respir Rev. (2021) 8:e000829. doi: 10.1186/s41100-020-000829

25. Raghu G, Remy-Jardin M, Myers JL, Richeldi L. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2018) 198:e44–68. doi: 10.1164/rccm.201807-1255ST

26. Katz A, Chatterjee S. Antisynthetase syndrome: prevalence of serositis in autoantibody subsets [abstract]. Arthritis Rheumatol. (2018) 70:153–4. doi: 10.1002/art.40357

27. Badshah A, Haider I, Perez S, Humayun M. Antisynthetase syndrome presenting as interstitial lung disease: a case report. J Med Case Rep. (2019) 13:241. doi: 10.1186/s13256-019-2146-0

28. Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. (2016) 118:39–45. doi: 10.1016/j.rmed.2016.07.009

29. Flaherty KR, Wells AU, Cotton V, Devraj A, Walsh SLE, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. (2019) 381:1718–27. doi: 10.1056/NEJMoa1908681

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Martínez A. Use of Electromyography in the diagnosis of inflammatory rheumatol 74:992. doi: 10.1001/jamaneurol.2017.0934

V , et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathies. J Clin Rheumatol. (2022) 61:1760–8. doi: 10.1093/rheumatology/keac115

Huang K, Aggarwal R. Antisynthetase syndrome: a distinct disease spectrum. J Schrderma Relat. Disord. (2020) 5:178–91. doi: 10.1177/1299380920900267

Baratella E, Marrocchio C, Cifaldi R, Santagigliana M, Bozzato AM, Crivelli P, et al. Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study. J Eur. Radiol. (2021) 31:90–6. doi: 10.1007/s00348-020-05300-3

Zhan Y, Xan W, Wang Y, Li Q, Shi X, Gao Y, et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm. Med. (2021) 21:57. doi: 10.1186/s12890-021-01399-5

Debray M, Morrie R, Revel M, Naccache J, Khalil A, Toper C, et al. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur. Radiol. (2015) 25:516–23. doi: 10.1007/s00330-014-3362-0

Adams TN, Batra K, Sihlan I, Anand V, Joens EK, Moore S, et al. Utility of bronchoalveolar lavage and lung biopsy in connective tissue diseases: pulmonary conditions beyond “the usual suspects”. Clin Exp. Respir. Med. (2021) 191:106697. doi: 10.1016/j.rmed.2021.106697

Flusher BM, VanderLaan PA, Nurhussien L, Rice MB, Hallowell RW. Pulmonary histopathology of interstitial lung disease associated with anti-synthetase antibodies. Respir. Med. (2021) 191:106697. doi: 10.1016/j.resmed.2021.106697

Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res. (2023) 65:800–8. doi: 10.1002/arcc.21895

Burge P, Reynolds J, Trotter S, Burge G, Walters G. Histologist's original opinion compared with multidisciplinary team in determining diagnosis in interstitial lung disease. Thorax. (2017) 72:280–1. doi: 10.1136/thoraxjnl-2016-208776

Chatterjee S, Prysson R, Farver C. Antisynthetase syndrome: not just an inflammatory myopathy. Cleve Clin. J Med. (2013) 80:655–66. doi: 10.1097/CMJ.0b013e31824b1271

Opinch A, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. (2021) 51:72–83. doi: 10.1016/j.semarthrit.2020.09.020

Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, et al. Short-term and long-term outcome of anti-Jo-1 positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. (2012) 41:890–9. doi: 10.1016/j.semarthrit.2011.09.008

Rider LG, Kooioli D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res. (2010) 62:465–72. doi: 10.1002/acr.20035

Bergoin C, Bure M, Tavernier YJ, Lamblin C, Maurage CA, Remy-Jardin M, et al. The anti-synthetase syndrome. Rev Mal Respir. (2002) 19:371–4.

Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J, et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. (2017) 74:992. doi: 10.1001/jamaneurol.2017.0934

Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert C, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology. (2022) 61:1760–8. doi: 10.1093/rheumatology/keac115

Gutiérrez Gutiérrez G, Barbosa López C, Navacerrada E, Miralles Martínez A. Use of Electromyography in the diagnosis of inflammatory myopathies. Rheumatol Clin. (2012) 8:195–200. doi: 10.1016/j.rheumac.2011.02.004

Boiko I, Louis SL, Salmon JH, Benveniste O, Allenbach Y, Maisonneuve T. Diagnostic accuracy of electromyogram for myositis [abstract]. Arthritis. Rheumatol. (2021) 73.
systemic inflammation in a single-center cohort study. *Front Immunol.* (2021) 12:729602. doi: 10.3389/fimmu.2021.729602

73. Carneiro C, O-Charoen P, Chatterjee S. Pulmonary hypertension in antisyntethase syndrome. In: ACR/ARHP Annual Meeting. Chicago (2018).

74. Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD, et al. Presence of anti-eukaryotic initiation factor-2β, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. *Rheumatology.* (2016) 57:712–7. doi: 10.1093/rheumatology/kew458

75. Hervier B, Meyer A, Dieval C, Uzunhan Y, Devilliers H, Launay D, et al. Pulmonary hypertension in antisyntethase syndrome: prevalence, astrology and survival. *Eur Respir J.* (2013) 42:1271–82. doi: 10.1183/09031936.00156312

76. Dieval C, Deligny G, Meyer A, Chzel P, Champiaux N, Lefèvre G, et al. Myocardiitis in patients with antisyntethase syndrome. *Medicine.* (2015) 94:e798. doi: 10.1097/MD.0000000000000798

77. du Fay de Lavallat J, Prepubois A, Wendebourge MJ, Kessenheimer E, Kyburz D, Daikeler T, et al. Skeletal muscle disorders: a noncardiac source of cardiac troponin T. *Circulation.* (2022) 145:1764–79. doi: 10.1161/CIRCULATIONAHA.121.055889

78. Greco M, García de Yébenes MJ, Alarcón I, Brandy-García A. Antisyntethase syndrome: non-antisynthetase antibodies, clinical manifestations and overlaps [abstract]. *Ann Rheum Dis.* (2019) 78:1789–90. doi: 10.1136/annrheumdis-2019-eular.7149

79. Tan EM, Felkamp TEW, Smolen JS, Butcher B. Range of antinuclear antibodies in “healthy” individuals. *Arthritis Rheumat.* (1997) 40:1601–11. doi: 10.1002/art.1780400909

80. Chan EKL, Damaoixeau J, Carballo OG, Conrad K. Report of the First International consensus on standardized nomenclature of antinuclear antibody HEP-2 cell patterns 2014–2015. *Front Immunol.* (2015) 6:412. doi: 10.3389/fimmu.2015.00412

81. Fritzler MJ, Choi MY, Mahler M. The antinuclear antibody test in the diagnosis of antisyntethase syndrome and other autoimmune myopathies. *J Rheumatol.* (2018) 45:441–445. doi: 10.3899/jrheum.170258

82. Cavazana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabelli N, et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. *J Immunol Methods.* (2016) 433:1–5. doi: 10.1016/j.jim.2016.02.017

83. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. *Ann Rheum Dis.* (2010) 69:1420–26. doi: 10.1136/ard.2009.127100

84. Aggarwal R, Dhillon N, Fertig N, Koonzt D. A Negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisyntethase syndrome. *J Rheumatol.* (2017) 44:223–9. doi: 10.3899/jrheum.160618

85. He J, Wei X, Sturgess A. Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort. *Rheumatology.* (2022) 1–7. doi: 10.1093/rheumatology/keac039

86. Chan EKL, Damaoixeau J, de Melo Cruvinel W, Carballo OG. Report on the Second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. * Lupus.* (2016) 25:797–804. doi: 10.1177/0961203316640920

87. Tansey SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. *Rheumatology.* (2020) 59:2109–14. doi: 10.1093/rheumatology/keaa021

88. To F, Ventin-Rodriguez C, Elkahfa S, Lilleker JB, Chino H. Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. *BMC Rheumatol.* (2020) 4:28. doi: 10.1186/s12899-020-01132-9

89. Ferreira JP, Almeida I, Martinho A, Cerveira C, Vasconcelos C. Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. *ISRN Rheumatol.* (2012) 2012:1–4. doi: 10.5402/2012/415272

90. Decker P, Moulinet T, Lopez B, Dubucquoi S. Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. *Eur J Intern Med.* (2021) 91:43–52. doi: 10.1016/j.ejim.2021.04.020

91. Zahid A, Chohan P, Sheeran T, Fahim A. A combined rheumatology/interstitial lung disease service: the Wolverhampton experience. *Chest.* (2019) 155:139A. doi: 10.1016/j.chest.2019.02.131

92. Bradley B, Branley H, Greaves M. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax.* (2008) 63:v1–58. doi: 10.1136/thx.2008.101691

93. Furini F, Carnevale A, Caso R, Guerri G, Cavagna L, Govoni M, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. *Front Med.* (2019) 6:246. doi: 10.3389/fmed.2019.00246

94. Charttrand S, Swigris JJ, Pekyova L, Chung J, Fischer A, A. Multidisciplinary evaluation helps identify the antisyntethase syndrome in patients presenting as idiopathic interstitial pneumonitis. *J Rheumatol.* (2016) 43:887–92. doi: 10.3899/jrheum.150966

95. Walsh SLE, Wells AU, Desai SR, Polleti V, Picozzi S, Dubini A, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. *Lancet Respir Med.* (2016) 4:557–65. doi: 10.1016/S2213-2600(16)30033-9

96. Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shoched G, Koslow M, Shirit D. Rheumatological assessment is important for interstitial lung disease diagnosis. *J Rheumatol.* (2018) 45:1509–14. doi: 10.3899/jrheum.171314

97. Ariz ZA, Wells AU, Hansell DM. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. *Thorax.* (2004) 59:506–11. doi: 10.1136/thorx.2003.020396

98. Salama K, Ramsundar N, Joshi V. Should a combined rheumatology-pulmonology interstitial lung disease service be confined to tertiary centres - a service evaluation [abstract]. *Ann Rheum Dis.* (2020) 79:1981. doi: 10.1136/annrheumdis-2020-eular.2023

99. Oldroyd AGS, Allard AB, Cullen JP, Chino H, Chung L, Fiorentino D, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. *Rheumatology.* (2021) 60:2615–28. doi: 10.1093/rheumatology/keab166